Authorized purpose: Notify hospital-network clinicians and neurovascular or neurosurgical specialists of suspected ICH on acute non-contrast head CT in parallel with standard-of-care interpretation; it is not a diagnostic device.
Clinical role
Notification and triage support operating in parallel with, and independent of, the standard-of-care workflow.
Images and patients
CT/CTA · Brain, with intracranial hemorrhage (ICH) subtypes including extradural, subdural, subarachnoid, intraparenchymal, and intraventricular hemorrhage.
Key limitation
Keep in mind: Notification and preview are informational and non-diagnostic; clinicians must review high-quality images on a diagnostic viewer and complete patient evaluation. The device does not alter or remove the original image, is not a substitute for standard of care, and must not be relied on to make or confirm a diagnosis.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Notify hospital-network clinicians and neurovascular or neurosurgical specialists of suspected ICH on acute non-contrast head CT in parallel with standard-of-care interpretation; it is not a diagnostic device.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain, with intracranial hemorrhage (ICH) subtypes including extradural, subdural, subarachnoid, intraparenchymal, and intraventricular hemorrhage. Input: DICOM-compatible non-contrast CT images of the head acquired in the acute setting, including stroke-protocol studies analyzed for suspected ICH.
Who uses it?Intended users: Hospital networks and trained clinicians, including neurovascular and neurosurgical specialists responsible for reviewing high-quality images and making care decisions.
What does the software produce?Output: Detection of suspected ICH and a notification with non-diagnostic preview images sent to a mobile application; the device does not mark or segment the original image and does not remove cases from the worklist.
What is its most important limitation?Key limitation: Notification and preview are informational and non-diagnostic; clinicians must review high-quality images on a diagnostic viewer and complete patient evaluation. The device does not alter or remove the original image, is not a substitute for standard of care, and must not be relied on to make or confirm a diagnosis.
Clinical takeaway. Clinical role: Notify hospital-network clinicians and neurovascular or neurosurgical specialists of suspected ICH on acute non-contrast head CT in parallel with standard-of-care interpretation; it is not a diagnostic device.
Evidence takeaway. Evidence from the reviewed source record: FDA K241719 reports a retrospective blinded study of 376 NCCT head studies, 35.90% ICH-positive and 64.09% normal, with ground truth from three U.S. board-certified neurologists. Primary sensitivity was 94.81% (95% CI 89.68%-97.43%), specificity 92.53% (88.50%-95.21%), accuracy 93.35% (90.37%-95.45%), and AUC 0.9367. A separate secondary workflow analysis used 128 eligible scans and reported time-to-notification of 0.37 +/- 0.20 minutes versus 18.3 +/- 14.2 minutes for standard-of-care time-to-open-exam.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Notify hospital-network clinicians and neurovascular or neurosurgical specialists of suspected ICH on acute non-contrast head CT in parallel with standard-of-care interpretation; it is not a diagnostic device.
Detection of suspected ICH and a notification with non-diagnostic preview images sent to a mobile application; the device does not mark or segment the original image and does not remove cases from the worklist.
Hospital networks and trained clinicians, including neurovascular and neurosurgical specialists responsible for reviewing high-quality images and making care decisions.
Notification and preview are informational and non-diagnostic; clinicians must review high-quality images on a diagnostic viewer and complete patient evaluation. The device does not alter or remove the original image, is not a substitute for standard of care, and must not be relied on to make or confirm a diagnosis.
FDA K241719 reports a retrospective blinded study of 376 NCCT head studies, 35.90% ICH-positive and 64.09% normal, with ground truth from three U.S. board-certified neurologists. Primary sensitivity was 94.81% (95% CI 89.68%-97.43%), specificity 92.53% (88.50%-95.21%), accuracy 93.35% (90.37%-95.45%), and AUC 0.9367. A separate secondary workflow analysis used 128 eligible scans and reported time-to-notification of 0.37 +/- 0.20 minutes versus 18.3 +/- 14.2 minutes for standard-of-care time-to-open-exam.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K241719 reports a retrospective blinded study of 376 NCCT head studies, 35.90% ICH-positive and 64.09% normal, with ground truth from three U.S. board-certified neurologists. Primary sensitivity was 94.81% (95% CI 89.68%-97.43%), specificity 92.53% (88.50%-95.21%), accuracy 93.35% (90.37%-95.45%), and AUC 0.9367. A separate secondary workflow analysis used 128 eligible scans and reported time-to-notification of 0.37 +/- 0.20 minutes versus 18.3 +/- 14.2 minutes for standard-of-care time-to-open-exam.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
NeuroICH regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K241719
Samplen=376
IndependenceIndependence not established
K241719
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241719. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM-compatible non-contrast CT images of the head acquired in the acute setting, including stroke-protocol studies analyzed for suspected ICH.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The packet describes a cloud-hosted image-analysis module, DICOM-compatible acquisition, and mobile-app preview/notification. It does not establish a specific PACS, RIS, EHR, or routing interface.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes an image analysis module hosted on cloud and a mobile application for previewing notifications, with images sent from the local hospital network to a remote location for storage, processing and analysis. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "NeuroICH mainly consists of an image analysis module hosted on cloud, and a mobile application for preview of notification and non-diagnostic images." … "use the similar process of automatic data identification and transfer to send images from the local hospital network to a remote location for image storage, processing and analysis.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Detection of suspected ICH and a notification with non-diagnostic preview images sent to a mobile application; the device does not mark or segment the original image and does not remove cases from the worklist.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Detection of suspected ICH and a notification with non-diagnostic preview images sent to a mobile application; the device does not mark or segment the original image and does not remove cases from the worklist.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes an image analysis module hosted on cloud and a mobile application for previewing notifications, with images sent from the local hospital network to a remote location for storage, processing and analysis. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "NeuroICH mainly consists of an image analysis module hosted on cloud, and a mobile application for preview of notification and non-diagnostic images." … "use the similar process of automatic data identification and transfer to send images from the local hospital network to a remote location for image storage, processing and analysis.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The packet describes a cloud-hosted image-analysis module, DICOM-compatible acquisition, and mobile-app preview/notification. It does not establish a specific PACS, RIS, EHR, or routing interface.
The SaveLife.AI trust center (SaveLife.AI is the d/b/a of applicant Neurocareai, Inc.) states HITRUST CSF Certified and HIPAA Compliant status, with a third-party HIPAA audit report and HITRUST CSF assessment report available under NDA; the page also cites FDA 510(k) K241719.
Vendor-wide
Checked 2026-10-27
Vendor statements, not attestations. The reports are NDA-gated and were not read; the trust center cites K241719 (NeuroICH) but does not scope the claims to any specific release; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K241719 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.
Modality
CT/CTA
Anatomy
Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings
Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.